Ann Rheum Dis ：PRINTO国际标准或可确定不活动性JDM！

2022-01-10 06:49:58 来源:

来自西方的一项多属国研究表明，孩童癫痫属国际试验组织起来（PRINTO）草拟了数据导向准则，以识别那些在病理上平庸为不反应性传染病的孩童型皮肌炎（JDM）病症。这些准则可可用病理研究、研究以及病理实践。该论文刊载在2013年第5期《癫痫学学术著作》[Ann Rheum Dis 2013;72:686-693]。孩童癫痫属国际试验组织起来（The Paediatric Rheumatology International Trials Organisation ，简称PRINTO）数据库还包括275实有反应性孩童型皮肌炎（JDM）病症，指标预期为24个同年。24个同年时，38实有病症脱离疗法，确定为病理不反应性JDM，并归入参照组。这些病症与还包括76实有研究终端有反应性传染病病症的随机样本进行尤其。学术界指标变异当前如肌肉力量/耐久、肌肉酶类、外科和病症的全面性传染病反应性/损伤指标，以及基于史籍和其他专门准则的不反应性传染病准则的持续性、基因表达和安德森卡帕双方同意（Cohen's κ agreement）。平庸最佳特征性不反应性传染病（持续性和基因表达＞0.8，Cohen's κ>0.8）的变异当前是徒手肌力体检（MMT）≥78，外科全面性指标肌肉活动度=0，外科全面性指标总传染病反应性（PhyGloVAS）≤0.2，孩童肌炎指标量表（CMAS）≥48，传染病活动满分≤3以及肌炎传染病反应性指标视觉模拟满分≤0.2。病症归类为放弃或不放弃疗法的不反应性传染病状态的最佳联合当前至少有以下四个准则之前的三个：肌酸激酶≤150，CMAS≥48，MMT≥78和PhyGloVAS≤0.2。24个同年后，96.8%（30/31）病症有不反应性传染病，脱离疗法；47.6%（69/145）病症有不反应性传染病，仍放弃疗法。与癫痫无关的拓展阅读：

2013年属国内外癫痫学术会议2013年属国内外癫痫学术会议哥伦比亚癫痫学会类风关疗法力荐抗击-TNF疗法与癫痫病症全身性风险降低无关之前华医学会第十七次全属国癫痫学术会议：痛风与不够高尿酸血症的最新方面Medscape：2011最受注目癫痫方面不够多个人信息劝点击：有关癫痫不够多讯息

The PRINTO criteria for clinically inactive disease in juvenile dermatomyositisOBJECTIVESTo develop data-driven criteria for clinically inactive disease on and off therapy for juvenile dermatomyositis (JDM).METHODSThe Paediatric Rheumatology International Trials Organisation (PRINTO) database contains 275 patients with active JDM evaluated prospectively up to 24 months. Thirty-eight patients off therapy at 24 months were defined as clinically inactive and included in the reference group. These were compared with a random sample of 76 patients who had active disease at study baseline. Individual measures of muscle strength/endurance, muscle enzymes, physician's and parent's global disease activity/damage evaluations, inactive disease criteria derived from the literature and other ad hoc criteria were evaluated for sensitivity, specificity and Cohen's κ agreement.RESULTSThe individual measures that best characterised inactive disease (sensitivity and specificity>0.8 and Cohen's κ>0.8) were manual muscle testing (MMT) ≥78, physician global assessment of muscle activity=0, physician global assessment of overall disease activity (PhyGloVAS) ≤0.2, Childhood Myositis Assessment Scale (CMAS) ≥48, Disease Activity Score ≤3 and Myositis Disease Activity Assessment Visual Analogue Scale ≤0.2. The best combination of variables to classify a patient as being in a state of inactive disease on or off therapy is at least three of four of the following criteria: creatine kinase ≤150, CMAS ≥48, MMT ≥78 and PhyGloVAS ≤0.2. After 24 months, 30/31 patients (96.8%) were inactive off therapy and 69/145 (47.6%) were inactive on therapy.CONCLUSIONPRINTO established data-driven criteria with clearly evidence-based cut-off values to identify JDM patients with clinically inactive disease. These criteria can be used in clinical trials, in research and in clinical practice.